Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

ONCR
Oncorus Inc
stock NASDAQ

At Close
2/3/2023 3:55:30 PM EST
0.4355USD-3.222%(-0.0145)425,669
0.4300Bid   0.4500Ask   0.0200Spread IEX
Pre-market
2/3/2023 9:28:30 AM EST
0.4631USD+2.911%(+0.0131)0
After-hours
2/3/2023 4:00:30 PM EST
0.4355USD0.000%(0.0000)0
OverviewOption ChainHistoricalExchange VolumeShort VolumeBorrow FeeFailure to DeliverTrendsNewsMore
open chart   
open chart   
Market Cap
11.311M
Industry
Biotechnology
ONCR Stats
Avg. Vol. 10 Day
403,682
Avg. Vol. 30 Day
700,326
Employees
82
Market Cap
11,311,300
Shares Out.
25,973,135
Float
14,305,224
On/Off Exchange
58%/42%
6 Month Beta
0.32
1 Year Beta
0.52
2 Year Beta
0.67
3 Year Beta
0.65
52 Week Low
0.23
52 Week High
3.26
SMA50
0.34
SMA200
0.82
1 Week
+8.31%
1 Month
+47.13%
3 Month
-24.06%
6 Month
-71.16%
1 Year
-85.14%
2 Year
-98.19%
Jan 3, 2022
07:00AM EST  Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.   GlobeNewswire Inc
Nov 23, 2021
07:00AM EST  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Nov 19, 2021
04:47PM EST  Oncorus Files Prospectus Supplement Related To Sales Of Shares Having Offering Price Of Up To $50M   Benzinga
Nov 18, 2021
07:55AM EST  The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings   Benzinga
Nov 17, 2021
07:00AM EST  Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Jefferies London Healthcare Conference.   GlobeNewswire Inc
More News
Profile
At Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. Oncorus is advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity to tumor cells. Its lead program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities.

ONCR Stock Summary

Oncorus Inc (NASDAQ:ONCR) stock price today is $0.4355, and today's volume is 425,669. ONCR is down -3.222% today. The 30 day average volume is 700,326. ONCR market cap is 11.311M with 25,973,135 shares outstanding.



Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC